# US 2024/0174606 A1 · Indole compounds, and preparation methods, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174606 A1
- Document ID: US20240174606A1
- Status: Published application
- Kind: A1
- Application number: 18/270,743
- Filed: 2022-09-02
- Published: 2024-05-30
- Earliest claimed: 2021-09-03
- Assignees: Shenzhen 01 Life Science and Technology Co., Ltd.
- Applicants: Shenzhen 01 Life Science and Technology Co., Ltd.
- Inventors: Xiaoqiang XU; Xiaokai WANG; Yao MA; Xianbin ZHONG
- Web page: https://patentgrep.com/patent/US20240174606A1

## CPC

- C07D 209/12: Radicals substituted by oxygen atoms
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A class of indole compounds is provided, their preparation methods and use thereof, which belong to the technical field of pharmaceutical chemistry. The compounds represented by formula I have a well therapeutic effect on atopic dermatitis.

## Claims

### Claim 1

A compound having a structure of formula I,
wherein,
W is COR2, or CR3R4OR5;
X is absent, or X is CO, or CR3R4;
Y is absent, or Y is O;
Z is absent, or Z is CR3R4;
R1 is selected from the group consisting of unsubstituted or substituted C1-20 alkyl, unsubstituted or substituted C2-20 alkenyl, unsubstituted or substituted aryl, heteroaryl, arylalkyl, heteroarylalkyl, and alkoxy;
R is selected from the group consisting of H, D, unsubstituted or substituted C1-6 alkyl, unsubstituted or substituted C2-6 alkenyl, unsubstituted or substituted aryl, heteroaryl, halogen, OR5, NR6R7, CO2R7, CONR6R7, OCOR8, NHCOR8, NHSO2R8, and CN;
each of R2, R3, R4, R6, R7, and R8 is independently selected from the group consisting of H, D, unsubstituted or substituted C1-6 alkyl, unsubstituted or substituted C2-6 alkenyl, unsubstituted or substituted aryl, and heteroaryl; and
R5 is H, D, or COR1.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound has a structure as shown in formula II:

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
W is COR2, or CR3R4OR5;
X is absent, or X is CO;
Y is absent, or Y is O;
Z is absent, or Z is CR3R4;
R1 is selected from the group consisting of unsubstituted or substituted C1-20 alkyl, unsubstituted or substituted aryl, and alkoxy;
R is H; and
each of R2, R3, R4, and R5 is H.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein: R1 is selected from the group consisting of unsubstituted or substituted C5-15 alkyl, acetoxyl-substituted aryl, (2,6-dichlorophenyl)amino-substituted aryl, and pentaoxapentadecanyl.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein
W is COH, or CH2OH;
each of X, Y, and Z is COOCH2, or CH2;
R1 is selected from the group consisting of C7-C15 alkyl, acetoxyl-substituted aryl, (2,6-dichlorophenyl)amino-substituted aryl, and pentaoxapentadecanyl; and
R is H.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein
W is COH;
each of X, Y, and Z is CH2;
R1 is selected from the group consisting of C7-C15 alkyl, acetoxyl-substituted aryl, (2,6-dichlorophenyl)amino-substituted aryl, and pentaoxapentadecanyl; and
R is H.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the compound is selected from the group consisting of:

### Claim 8 (depends on 7)

The compound according to claim 7, wherein
the Compound 4 has characteristic peaks at 2θ of 4.9±0.2°, 7.3±0.2°, 9.9±0.2°, 14.9±0.2°, and 22.0±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 8 has characteristic peaks at 2θ of 5.2±0.2°, 11.6±0.2°, 12.6±0.2°, 16.0±0.2°, and 19.3±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 9 has characteristic peaks at 2θ of 12.3±0.2°, 14.9±0.2°, 19.9±0.2°, 23.4±0.2°, and 27.3±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 22 has characteristic peaks at 2θ of 3.4±0.2°, 5.3±0.2°, 6.9±0.2°, 10.2±0.2°, and 19.9±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 23 has characteristic peaks at 2θ of 10.6±0.2°, 11.0±0.2°, 18.4±0.2°, 21.2±0.2°, and 21.7±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 24 has characteristic peaks at 2θ of 4.4±0.2°, 6.6±0.2°, 8.9±0.2°, 21.0±0.2°, and 22.6±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 26 has characteristic peaks at 2θ of 3.6±0.2°, 10.5±0.2°, 11.8±0.2°, 13.9±0.2°, and 19.7±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 27 has characteristic peaks at 2θ of 6.5±0.2°, 10.2±0.2°, 13.2±0.2°, 15.0±0.2°, and 23.8±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation;
the Compound 35 has characteristic peaks at 2θ of 12.4±0.2°, 14.7±0.2°, 15.3±0.2°, 17.3±0.2°, and 23.5±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation; and
the Compound 41 has characteristic peaks at 2θ of 3.1±0.2°, 5.2±0.2°, 6.7±0.2°, 10.2±0.2°, and 19.9±0.2° in an X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 9 (depends on 1)

A pharmaceutical composition, comprising the compound according to claim 1, and a pharmaceutically acceptable excipient.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, wherein a dosage form of the pharmaceutical composition is a tablet, a dispersing agent, a tincture, a gel, a capsule, a spray, a suppository, an oral liquid, or a granule.

### Claim 11 (depends on 9)

The pharmaceutical composition according to claim 9, wherein a dosage form of the pharmaceutical composition is a topical preparation.

### Claim 12 (depends on 1)

A method of treating at least one of dermatitis and an immune system disease in a mammal in need thereof, comprising administering the compound according to claim 1.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the dermatitis is atopic dermatitis and the immune system disease is asthma.

### Claim 14 (depends on 2)

The compound according to claim 2, wherein:
W is COR2, or CR3R4OR5;
X is absent, or X is CO;
Y is absent, or Y is O;
Z is absent, or Z is CR3R4;
R1 is selected from the group consisting of unsubstituted or substituted C1-20 alkyl, unsubstituted or substituted aryl, and alkoxy;
R is H; and
each of R2, R3, R4, and R5 is H.

### Claim 15 (depends on 2)

The compound according to claim 2, wherein:
W is COH, or CH2OH;
each of X, Y, and Z is COOCH2, or CH2;
R1 is selected from the group consisting of C7-C15 alkyl, acetoxyl-substituted aryl, (2,6-dichlorophenyl)amino-substituted aryl, and pentaoxapentadecanyl; and
R is H.
